Literature DB >> 21651946

Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines.

Hung-Ju Wei1, Weihau Chang, Shih-Chang Lin, Wen-Chun Liu, Ding-Kao Chang, Pele Chong, Suh-Chin Wu.   

Abstract

Influenza virus-like particles (VLPs) are noninfectious and the assembly of influenza VLPs depends on the interactions of M1 proteins and/or other viral surface proteins, such as HA, NA, and M2, with the cellular lipid membranes. In this study we propose that M2 protein can be used as a molecular fabricator without disrupting the assembly of VLPs and while retaining the native structures of HA and NA envelope protein oligomers on the particle surfaces. First, we demonstrated that influenza VLPs can be fabricated by the M2 fusion of enhanced green fluorescent protein for imaging single virus entering A549 cells. Second, we engineered two molecular adjuvants (flagellin and profilin) fused to M2 protein to generate molecular adjuvanted VLPs. Theses molecular adjuvanted VLPs had stimulatory functions, including increasing TNF-α production and promoting the maturation of dendritic cells. Immunization of mice with molecular adjuvanted VLPs also enhanced the response of the neutralizing antibodies against homologous and heterologous H5N1 viruses. The results can provide useful information for imaging single viruses and designing novel vaccines against influenza virus infection.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21651946     DOI: 10.1016/j.vaccine.2011.05.077

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Development of Rous sarcoma Virus-like Particles Displaying hCC49 scFv for Specific Targeted Drug Delivery to Human Colon Carcinoma Cells.

Authors:  Tatsuya Kato; Megumi Yui; Vipin Kumar Deo; Enoch Y Park
Journal:  Pharm Res       Date:  2015-06-06       Impact factor: 4.200

2.  Expression of human rotavirus chimeric fusion proteins from replicating but non disseminating adenovectors and elicitation of rotavirus-specific immune responses in mice.

Authors:  Aurélie Girard; Elodie Roques; Marie-Claude St-Louis; Bernard Massie; Denis Archambault
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

3.  Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Authors:  Wen-Chun Liu; Chia-Ying Lin; Yung-Ta Tsou; Jia-Tsrong Jan; Suh-Chin Wu
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

Review 4.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

5.  Different immunity elicited by recombinant H5N1 hemagglutinin proteins containing pauci-mannose, high-mannose, or complex type N-glycans.

Authors:  Shih-Chang Lin; Jia-Tsrong Jan; Ben Dionne; Michael Butler; Ming-Hsi Huang; Chung-Yi Wu; Chi-Huey Wong; Suh-Chin Wu
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

6.  Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles.

Authors:  Shih-Chang Lin; Yu-Fen Lin; Pele Chong; Suh-Chin Wu
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

Review 7.  Fluorosomes: fluorescent virus-like nanoparticles that represent a convenient tool to visualize receptor-ligand interactions.

Authors:  Daniela Wojta-Stremayr; Winfried F Pickl
Journal:  Sensors (Basel)       Date:  2013-07-08       Impact factor: 3.576

Review 8.  Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development.

Authors:  Peter Pushko; Irina Tretyakova
Journal:  Viruses       Date:  2020-05-08       Impact factor: 5.048

9.  Progress in the development of virus-like particle vaccines against respiratory viruses.

Authors:  Fu-Shi Quan; Swarnendu Basak; Ki-Back Chu; Sung Soo Kim; Sang-Moo Kang
Journal:  Expert Rev Vaccines       Date:  2020-01-18       Impact factor: 5.217

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.